THE ANALYSIS STUDY OF OSTEOPOROSIS AND FRACTURE RISK: A TEN YEARS SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/nagrwm92Keywords:
Osteoporosis, fracture, risk, FRAX, BMDAbstract
Background: Microarchitecture degeneration and reduced bone mass, which increase fragility and fracture susceptibility, are hallmarks of osteoporosis, a systemic skeletal disorder. Disease has a substantial effect on fracture healing as well as bone mass and microstructure. More accurate fracture risk assessment and a wider range of treatment choices are the results of research advances. Effective treatment regimens for osteoporosis have been aided by the fracture risk assessment tool (FRAX), which has had a substantial impact on clinical decision-making and intervention levels.
Methods: Following PRISMA 2020 guidelines, this systematic review concentrated on full-text English literature published between 2014 and 2024. Editorials and review articles that appeared in the same journal as the submission were not accepted without a DOI. A number of websites, including ScienceDirect, PubMed, and SagePub, were utilized to gather the literature.
Result: The study looked at more than 4,000 publications using reputable sources including Science Direct, SagePub, and PubMed. After it was decided that eight publications needed greater investigation, a more extensive review of the entire literature was carried out.
Conclusion: Studies have shown that osteoporosis can lead to fractures, with the Fracture Risk Assessment Tool (FRAX) and Bone Mineral Density (BMD) testing being used to assess fracture risk in women. Studies have shown that bone anabolic treatments can reduce fracture risk, but the certainty of these results is low due to the small number of studies.
References
Compston, J. E., Mcclung, M. R., & Leslie, W. D. (2019). Osteoporosis. 393, 364–376. https://doi.org/10.1016/S0140-6736(18)32112-3
Schuit, S. C. E., Klift, M. Van Der, Weel, A. E. A. M., Laet, C. E. D. H. De, Burger, H., Seeman, E., Hofman, A., Uitterlinden, A. G., Leeuwen, J. P. T. M. Van, & Pols, H. A. P. (2004). Fracture incidence and association with bone mineral density in elderly men and women : the Rotterdam Study. 34, 195–202. https://doi.org/10.1016/j.bone.2003.10.001
Siris, E. S., Chen, Y., Abbott, T. A., Barrett-connor, E., Miller, P. D., Wehren, L. E., & Berger, M. L. (2015). Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures. 164.
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Robinson, V., Coyle, D., & Tugwell, P. (2008). Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. The Cochrane database of systematic reviews, (1), CD001155. https://doi.org/10.1002/14651858.CD001155.pub2
Kendler, D. L., Marin, F., Zerbini, C. A. F., Russo, L. A., Greenspan, S. L., Zikan, V., Bagur, A., Malouf-sierra, J., & López-romero, P. (2017). Articles Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis ( VERO ): controlled trial. 6736(17), 1–11. https://doi.org/10.1016/S0140-6736(17)32137-2
Saag, K. G., Petersen, J., Brandi, M. L., Thomas, T., Ph, D., Maddox, J., Fan, M., Ph, D., Meisner, P. D., Pharm, D., & Grauer, A. (2017). Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. 1–11. https://doi.org/10.1056/NEJMoa1708322
Händel, M. N., Cardoso, I., von Bülow, C., Rohde, J. F., Ussing, A., Nielsen, S. M., Christensen, R., Body, J.-J., Brandi, M. L., Diez-Perez, A., Hadji, P., Javaid, M. K., Lems, W. F., Nogues, X., Roux, C., Minisola, S., Kurth, A., Thomas, T., Prieto-Alhambra, D., … Abrahamsen, B. (2023). Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ (Clinical Research Ed.), 381, e068033. https://doi.org/10.1136/bmj-2021-068033
Kanis, J.A. (2007) Assessment of Osteoporosis at the Primary Health Care Level. Technical Report, World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield.
Vandenput, L., Johansson, H., McCloskey, E. V, Liu, E., Åkesson, K. E., Anderson, F. A., Azagra, R., Bager, C.
L., Beaudart, C., Bischoff-Ferrari, H. A., Biver, E., Bruyère, O., Cauley, J. A., Center, J. R., Chapurlat, R., Christiansen, C., Cooper, C., Crandall, C. J., Cummings, S. R., … Kanis, J. A. (2022). Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International : A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 33(10), 2103–2136. https://doi.org/10.1007/s00198-022-064356
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008). FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 19(4), 385–397. https://doi.org/10.1007/s00198-007-0543-5
Kanis, J. A., Harvey, N. C., Johansson, H., Liu, E., Vandenput, L., Lorentzon, M., Leslie, W. D., & McCloskey, E. V. (2020). A decade of FRAX: how has it changed the management of osteoporosis?. Aging clinical and experimental research, 32(2), 187–196. https://doi.org/10.1007/s40520-019-01432-y
Fink, H. A., MacDonald, R., Forte, M. L., Rosebush, C. E., Ensrud, K. E., Schousboe, J. T., Nelson, V. A., Ullman, K., Butler, M., Olson, C. M., Taylor, B. C., Brasure, M., & Wilt, T. J. (2019). Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Annals of internal medicine, 171(1), 37–50. https://doi.org/10.7326/M19-0533
Kim, K.-T., Lee, Y.-S., & Han, I. (2020). The Role of Epigenomics in Osteoporosis and Osteoporotic Vertebral Fracture. International Journal of Molecular Sciences, 21(24). https://doi.org/10.3390/ijms21249455
Shevroja, E., Cafarelli, F. P., Guglielmi, G., & Hans, D. (2021). DXA parameters, Trabecular Bone Score (TBS) and Bone Mineral Density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis. Endocrine, 74(1), 20–28. https://doi.org/10.1007/s12020-021-02806-x
Imamudeen, N., Basheer, A., Iqbal, A. M., Manjila, N., Haroon, N. N., & Manjila, S. (2022). Management of Osteoporosis and Spinal Fractures: Contemporary Guidelines and Evolving Paradigms. Clinical Medicine & Research, 20(2), 95–106. https://doi.org/10.3121/cmr.2021.1612
Kostenuik, P. J., Binkley, N., & Anderson, P. A. (2023). Advances in Osteoporosis Therapy: Focus on Osteoanabolic Agents, Secondary Fracture Prevention, and Perioperative Bone Health. Current Osteoporosis Reports, 21(4), 386–400. https://doi.org/10.1007/s11914-023-00793-8
Schini, M., Johansson, H., Harvey, N. C., Lorentzon, M., Kanis, J. A., & McCloskey, E. V. (2024). An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. Journal of Endocrinological Investigation, 47(3), 501–511. https://doi.org/10.1007/s40618-023-02219-9
Baldini, M., Grossi, E., Cappellini, M. D., Messina, C., Marcon, A., Airaghi, L., Guglielmi, G., & Ulivieri, F. M. (2017). iMedPub Journals The Role of Trabecular Bone Score and Hip Geometry in Thalassemia Major : A Neural Network Analysis Keywords : Introduction. 1–9. https://doi.org/10.21767/2394-3718.100025
Leslie, W. D., Shevroja, E., Johansson, H., McCloskey, E. V., Harvey, N. C., Kanis, J. A., & Hans, D. (2018). Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 29(3), 751–758. https://doi.org/10.1007/s00198-018-4405-0
Shoback, D., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Eastell, R. (2020). Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. The Journal of clinical endocrinology and metabolism, 105(3), dgaa048. https://doi.org/10.1210/clinem/dgaa048
Kanis, J. A., Cooper, C., Rizzoli, R., Reginster, J. Y., & Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 30(1), 3–44. https://doi.org/10.1007/s00198-018-4704-5
Body, J. J., Marin, F., Kendler, D. L., Zerbini, C. A. F., López-Romero, P., Möricke, R., Casado, E., FahrleitnerPammer, A., Stepan, J. J., Lespessailles, E., Minisola, S., & Geusens, P. (2020). Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 31(10), 1935–1942. https://doi.org/10.1007/s00198-020-05463-4
Adams, A. L., Adams, J. L., Raebel, M. A., Tang, B. T., Kuntz, J. L., Vijayadeva, V., McGlynn, E. A., & Gozansky, W. S. (2018). Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 33(7), 1252–1259. https://doi.org/10.1002/jbmr.3420
Curtis JR, Chen R, Li Z, Arora T, Saag K, Wright NC, Daigle S, Kilgore M, Delzell E. The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-impact-of-the-duration-of-bisphosphonate-drug-holidays-on-hip-fracturerates/. Accessed June 8, 2024
Yang, Y., Xie, J., Chaugule, S., Wang, D., Kim, J., Kim, J., Tai, P. W. L., Seo, S., Gravallese, E., Gao, G., & Shim, J. (2020). Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy. Molecular Therapy: Methods & Clinical Development, 17(June), 922–935. https://doi.org/10.1016/j.omtm.2020.04.010
Lin, C., Yu, S., Jin, R., Xiao, Y., Pan, M., Pei, F., Zhu, X., Huang, H., Zhang, Z., Chen, S., Liu, H., & Chen, Z. (2019). Circulating miR-338 Cluster activities on osteoblast differentiation: Potential Diagnostic and Therapeutic Targets for Postmenopausal Osteoporosis. Theranostics, 9(13), 3780–3797. https://doi.org/10.7150/thno.34493
Mccloskey, E. V, Johansson, H., Oden, A., Austin, M., Siris, E., Wang, A., Lewiecki, E. M., Lorenc, R., Libanati, C., & Kanis, J. A. (2012). J BMR Denosumab Reduces the Risk of Osteoporotic Fractures in Postmenopausal Women , Particularly in Those With Moderate to High Fracture Risk as Assessed With FRAX. 27(7), 1480– 1486. https://doi.org/10.1002/jbmr.1606
Kanis, J. A., Johansson, H., Oden, A., & McCloskey, E. V. (2009). Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone, 44(6), 1049–1054. https://doi.org/10.1016/j.bone.2009.02.014
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
